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so called “PET-RT-Hodgkin”, a survey focusing on the target 
volumes concepts (IN, IF and IS) and the use PET-CT in 
treatment position was sent to 35 French academic centers 
(university hospitals and cancer centers) through the SFRO 
(French Society for Radiation Oncology). 
Results: Returns were obtained from 28 of the 35 centers 
contacted (80%). Of them, 10.7% were treating less than 5 
patients per year, 28.6%, from 5 to 10, 46.4% from 10 to 20, 
and 14.3% more than 20. The radiation therapists in charge 
were 19.0 ± 9.8 years of experience, including 14.9 ± 10.1 in 
the treatment of Hodgkin lymphoma. 86% of practitioners 
said that they were comfortable with the 3 concepts of 
target volume. Fifteen (53.6%) stated that IN was a standard 
and routinely use it; 8 answered that they were applying IS 
(28.6%). Five responded that IF was their standard of care, 
off-study (17.9%). If all used PET scans to define the target 
volumes; 19 centers offered the opportunity to perform it in 
treatment position (67.9%). Three radiotherapists admitted 
having difficulties in accessing it (10.7%) and six reported no 
access at all (21.4%). In 5 centers, patients were referred 
after chemotherapy and therefore with no possibility to 
perform this examination (17.9%). While most declared 
having a collaboration with a nuclear medicine physician, 
53.6% of the radiotherapists were interested in implementing 
an expert PET images review network. 
 
Conclusion: In routine, the definition of target volumes and 
access to the PET-CT in treatment position remain 
heterogeneous. The PET-RT-Hodgkin group aims to harmonize 
the conditions of realization of PET and justify the means to 
implement  
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Purpose or Objective: High-dose chemotherapy (HDCT) 
followed by autologous stem cell transplantation (ASCT) is 
the standard of care for relapsed or primary refractory 
Hodgkin’s lymphoma (HL) after first line treatment. The role 
of involved-field radiotherapy (IFRT) is controversial in this 
setting. Aim of this retrospective study was to investigate for 
a possible role for IFRT by comparing patients who received 
IFRT (prior or after ASCT) and patients who received salvage 
chemotherapy (CT) alone. 
 
Material and Methods: We enrolled 73 consecutive HL 
patients treated with ASCT between 2003 and 2013. Twenty-
one patients (28.8%) received pre (7 patients) or post (14 
patients) ASCT radiotherapy. A Cox regression analysis was 
performed to evaluate the prognostic role of any risk factor. 
OS and PFS were calculated from the first day of HDCT. 
Response to HDCT and ASCT were evaluated with PET scan 
and defined according to Cheson’s criteria. 
 
Results: Median follow up was 47 months (range 1-145) for 
the entire population. Population characteristics by 
treatment modality are summarized in Table 1.  
 
 
PFS and OS in the overall population were respectively 61.4% 
and 68.1% at 5 years. At the univariate analysis, advanced 
stage at relapse (HR 2.65, p = 0.026), persistent disease prior 
to ASCT (HR 2.53, p = 0.05) and IPS score ≥2 (HR 2.49, p = 
0.04) affected OS, while advanced stage at relapse (HR 2.77, 
p = 0.007) and persistent disease prior to ASCT (HR 2.85, p = 
0.01) were related to worse PFS. The Cox regression 
confirmed persistent disease prior to ASCT (HR 3.65, p = 
0.013) and stage III-IV at relapse (HR 3.65, p = 0.013) as 
associated to an increased risk of death. OS at 3 and 5 years 
was slightly better in patients receiving RT (86.5% and 78.7% 
respectively) compared to patients treated with CT alone 
(76.8% and 65.9%), even without reaching statistical 
significance (p = 0.42). A similar faint benefit was also 
observed in term of PFS (p = 0.39). We then performed a 
subgroup analysis in patients with progressive or relapsed 
stage I-II disease (N = 26) who failed induction CT prior to 
ASCT: 14 received IFRT (pre or post ASCT) and 12 CT alone. 
OS rates at 3 and 5 years were higher for the IFRT group 
(92.3% and 79.1% respectively) compared to CT alone group 
(61.9% and 51.6% respectively), even if this difference was 
not significant at the log-rank test (p = 0.13), probably due to 
the small numbers (Figure 1). Similarly, PFS was higher in 
patients receiving IFRT (69.6% vs 50% at 3 years), again 
without reaching a statistical significance (p = 0.22). 
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Conclusion: In our cohort, IFRT did not result to be 
associated to a PFS or OS benefit vs CT alone in the overall 
population. IFRT seemed to provide a survival benefit at 3 
and 5 years compared to CT alone (92.3% vs 61.9% and 79.1% 
vs 51.6%) in patients with stage I-II disease at relapse and 
with persistent disease prior to ASCT. A larger sample size is 
needed to further explore the effect of IFRT in this particular 
setting. 
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Purpose or Objective: Desmoplastic small round cell tumor 
(DSRCT) is a rare peritoneal tumor affecting predominantly 
children and young adult Caucasian males with a high rate of 
local failure after surgery. We performed a multicentric 
retrospective study to identify the prognostic impact of 
adjuvant abdominal radiotherapy. 
 
Material and Methods: All patients treated for primary 
abdominal DSRCT in 8 French centers from 1991 to 2014 were 
included. Patients were retrospectively staged into 3 groups: 
group A treated with adjuvant radiotherapy (RT) after 
cytoreductive surgery, group B without RT after 
cytoreductive surgery and group C by exclusive 
chemotherapy. Peritoneal progression-free survival (PPFS), 
progression-free survival (PFS) and overall survival (OS) were 
evaluated. We also performed a direct comparison between 
group A and B to evaluate RT after cytoreductive surgery. RT 
was also evaluated according to completeness of surgery: 
complete cytoreductive surgery (CCS) or incomplete 
cytoreductive surgery (ICS). 
 
Results: Thirty-seven (35.9%), thirty-six (34.9%) and thirty 
(28.0%) patients were included in group A, B and C, 
respectively. Three-year OS was 61.2% (41.0-76.0), 37.6% 
(22.0-53.1), and 17.3% (6.3-32.8) for group A, B and C, 
respectively. OS, PPFS and PFS differed significantly between 
the 3 groups (p<0.001; p<0.001 and p<0.001, respectively). 
OS and PPFS were higher in group A (RT group) compared to 
group B (no RT group) (p=0.045 and p=0.006, respectively). 
Three-year PPFS was 23.8% (10.3-40.4) for group A and 
12.51% (4.0-26.2) for group B. After CCS, RT improved PPFS 
(p=0.024) but differences in OS and PFS were not significant 
(p=0.40 and p=0.30, respectively). After ICS, RT improved OS 
(p=0.044). A trend of PPFS and PFS increase was observed but 
the difference was not statistically significant (p=0.073 and 
p=0.076). 
 
Conclusion: Adjuvant radiotherapy as part of multimodal 
treatment seems to confer oncological benefits for patients 
treated for abdominal DSRCT after cytoreductive surgery and 
perioperative chemotherapy.This study is the largest series 
evaluating DSRCT treatment and the first of its kind 
comparing patients who received RT after cytoreductive 
surgery with patients who did not. 
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Purpose or Objective: To compare Quality of Life (QoL) 
outcomes in patients (pts) with Malignant Spinal Cord 
Compression (MSCC) not proceeding with surgical 
decompression and treated by External Beam Radiation 
Therapy (EBRT) with one of two Fractionation Schedules (FS). 
 
Material and Methods: ICORG 05-03 was an ICH-GCP 
compliant prospective (1.1) randomised non-inferiority phase 
III trial comparing two FS: arm 1 (control): 20Gy/5 Fractions 
(#) vs. arm 2 (experimental): 10Gy/1#, with 80% power, 5% 
significant level and 0.4 non-inferiority margin. While the 
primary end point of this trial (previously presented (ASTRO 
2014)) was change in mobility at 5 weeks (wks), the current 
focus is on a secondary endpoint, QoL (EORTC QLQ-C30 
questionnaire).  
 
Results: From 2006 to 2014, 5 institutions accrued 115 
eligible pts (2 non-eligible pts, no treatment allocation 
violation). 70 pts with QoL data at 5 wks were evaluable. 
Baseline characteristics were balanced between arms [♀/♂: 
30/40, median age: 69 (range: 30-87)]. Analysis showed a 
statistically significant benefit of radiotherapy (RT) for ‘Pain 
interfered with daily activities’ but not for Overall OoL. 
There was no statistically significant benefit between arms 
for either: 1. Overall QoL (mean change from pre-treatment 
.52 in arm 1 vs. .21 in arm 2; 95% CI: -0.84 – 1.45, p = 0.596); 
2. Pain interfered with daily activities (mean change: .84 in 
arm 1 vs. 1.00 in arm 2; 95% CI: -0.66 – .98, p = 0.698). A 
non-planned exploratory regression analysis checked for 
independent prognostic factors for less pain at 5 wks. 
Multiple regression analysis revealed baseline pain as the 
strongest unique and statistically significant contributor to 
explaining less pain at 5-wks (beta = -0.63; p=0.002).  
Exploratory analyses were also conducted to characterise pts 
dying at <5 wks,who might not benefit from RT. Primary 
malignancy (Chi-square test: Χ2 (3, n=106) = 15.6, p = 0.001, 
phi = 0.38) and initial mobility status (Chi-square test, Χ2 (2, 
n=106) = 11.0, p = 0.004, phi = 0.32.) were found to be 
associated with a life expectancy <5 wks. 67% of lung and 13% 
of breast cancer pts died before 5 wks, as did 49% of bed-
bound and 15% of pts who could walk unaided.  
 
Conclusion: With respect to QoL, primary RT significantly 
improves the pain related variables used in the trial, with 
10Gy/1# FS being at least equivalent to 20Gy/5#. Baseline 
pain is the most significant independent prognostic factor for 
less pain at 5 wks. Tumour site and mobility should be 
considered when offering RT treatment to similar pts. 
 
 
 
 
